Arvinas (ARVN) logo

Arvinas (ARVN) stock

Protein-removing therapies , market cap $450M

$6.82
-0.73%

Why is ARVN down?

Down 6% on Nov 3, and still 9% under its Nov 2 close.

  • Its Nov 3 results: net income was a loss of $53.9M, from a loss of $35.1M a year before. It fell 6% on Nov 3.

Sources: Price history, Nov 3, 2026; Company release, Nov 3, 2026

−3Long-term trend below a falling 200-day average, down over one year, down over two years

Tell me next time ARVN moves

Free account, no card. An optional alert when ARVN moves or its score changes.Pro, 7 days free with a card. An optional alert when ARVN moves or its score changes.

Or see it live, free until tomorrow morning. No account.
1 more reason, free with an account →1 more reason why ARVN fell on Nov 3, from its filings, with the other side, the timeline, and its peers, for Pro members.
Quality Score
-4
Poor
In its industry
#74of 89
Checks firing
1of 14
Transition
From 52-week high
-53.0%
under its best in a year

ARVN's Quality Score was unchanged on Fri, Nov 13, at -4.

Follow ARVN's trial news. Pro members can get an alert when Arvinas files news, and see its trials, share raises, and its CEO's filings.

Get an alert when ARVN files news on its trialsSee it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“…commitment to share clinical data from three Phase 1 programs - ARV-393, ARV-027 and ARV-6723 - in 4Q 2026…”Trial data · SEC filing · Nov 3

Key facts on ARVN

Key facts on ARVN
Holding it backSales down 12% on the year
Latest filing8-K, Nov 3 Reported its quarterly results
1 more reason behind ARVN's -4, free with an account →1 more reason behind ARVN's -4, for Pro members.

ARVN in the news

Thu Nov 5Arvinas to Present Preliminary Clinical Data from Early GlobeNewswire and 2 more ARVN closed −11.7% that day.

What's next

Wed Nov 18: Jefferies 17th Annual London Global…Investor conference · date confirmed.

Expected to report Tue Feb 23, before the open

After its last 4 reports it closed +1.4% on average, higher 2 of 4 times.

1 more date ahead: the conference, for Pro members.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

ARVN catalysts

Coming up

7 more coming up and 5 past catalysts since 2021, with sizes and sources, for Pro members.

What's next for ARVN, and how long its cash lasts

Next step the company has named

Q4 2026“– Reaffirmed commitment to share clinical data from three Phase 1 programs - ARV-393, ARV-027 and ARV-6723 - in 4Q 2026 and 2027 –”Trial data · SEC filing · Nov 3

What it means: the first look at a trial’s main results, as the company reports them.

Lead program
ARV-393 · Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL) · Phase 1
Its trial
ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.Phase 1 · Recruiting · 329 people · main data estimated Mar 2028 · NCT06393738

2 more trials, 1 with data due this year, 7 more milestones and 54 filings, for Pro members.

Cash runway

The company says its cash lasts into the second half of 2028 (8-K, Nov 3).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

  • Shelf registration (S-3, filed Nov 3, 2026)
  • At-the-market share sales program (S-3, filed Nov 3, 2026)

For Pro members: the amounts, and the share count against a year ago.

Insiders

An officer, David K. Loomis, sold 232 shares on Nov 9, under a planned sale. 19 more insider trades this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Randy Teel’s 13 filings and quotes.

Get an alert when ARVN files news on its trialsA free account. No card.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 150 dates, ranked →

How ARVN ranks in Pharma

ARVN is #74 of 89 by Quality Score.

How ARVN ranks in Pharma
RankStockQuality Score
74Arvinas (ARVN) logoARVNArvinas-4

More in Pharma

When does ARVN report earnings, and what happens after?

Expected to report Tue Feb 23, before the open (in 99 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What ARVN reported on Nov 3, 2026

The quarter

A loss of $0.82 a share, from $0.48.

“The decrease in R&D expenses of $17.8 million for the quarter was primarily due to a decrease in external expenses of $10.5 million, and a decrease in compensation and related personnel expenses of $6.5 million, which are not allocated by program.”

The quarter that ended Sep 30, from the company's press release

The press releaseThe filing on EDGAR

Where the sales came from

ARVN's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

The numbers

Market value
$450M
today
Sales
$275M
down 11.8% on the year
Free cash flow
-$160M
last 12 months

Sales grew 26% a year over 3 years, fiscal 2022 to 2025.

Its share count grew 12% a year over 5 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on ARVN: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-0.9%+11.7%-5.7%
May 12Aug 4Nov 3
ReportedGapReaction5
days
Nov 3, 2026Before open-8.1%-5.7%-10.1%
Aug 4, 2026Before open+3.4%+11.7%+11.5%
May 12, 2026Before open+1.8%-0.9%-9.1%

ARVN closed higher after 2 of its last 4 reports.

All 4 reports, and ARVN's Quality Score going into each

ARVN sales and profit by year

Sales and profit by year

Sales grew in four of the last seven years, to $263M in 2025. It lost money in each of the eight years.

ARVN has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on ARVN, and all 14 on every stock.Get in free →

ARVN RSI on Nov 13: 42.3, below its 50-day and 200-day averages

Not scored

RSI 42.3, MACD below signal, below both averages. Not scored.

The deep dive on ARVN

  • What it does and how it makes money3 findings"Under the Novartis License Agreement … as well as tiered royalties based upon worldwide net sales of luxdegalutamide (ARV-766) …" (10-K for fiscal 2025)SEC filing · Feb 24, 2026
  • Where it stands2 findingsFor Pro members2 findings on where ARVN stands: its cash, debt, and share count, for Pro members
  • What changed in its filings4 findings"On June 6, 2023, Merck & Co., Inc., filed a lawsuit against HHS and CMS asserting that, among other things, the IRA’s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S. Constitution." (10-K for fiscal 2025)SEC filing · Feb 24, 2026A new heading in its "Risk Factors" this year: "Our cost savings plan and the associated workforce reductions implemented in April 2025 and September 2025 may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 24, 2026, against the one of Feb 11, 2025
  • Who holds and trades it2 findingsFor Pro members2 findings on who holds and trades ARVN, for Pro members

8 more findings on ARVN, each with its source, for Pro members.

ARVN share count over time

Shares: 10.7% fewer than a year ago (to Sep 30).

Shares of ARVN outstanding, as filed
Shares
outstanding
As
of
65.5MOct 30, 2026
65.4MJul 31, 2026
64.5MMay 7, 2026
64MFeb 20, 2026
Offerings, shelves, and splits of ARVN, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3)Nov 3, 2026
Registered shares for a later sale (S-3ASR)Dec 8, 2023

ARVN insider trades

One insider sold $20K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellRandy Teel$20KPresident and CEOat $9.04 on May 21, filed May 22

ARVN's officers and directors

Officers and directors with a Form 4 in the last 12 months.

4 more officers and directors file at ARVN.

See insider trades by person

Which ETFs hold ARVN?

In ETFs: ARVN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Arvinas

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

246 employeesNew Haven, CTarvinas.com

What Arvinas says it competes with

“The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products.”

From its annual report, SEC filing · Feb 24, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on ARVN and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn ARVN's score around: 8 things
  • 4 more filings explained, a plain line each
  • 2 more things pulling ARVN's score down
BreakawayMay 22Randy Teel sold ARVN$20K at $9.04, filed May 22

Alerts are optional.

See ARVN's 14 chart checks

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 16, 2026: ARVN's Quality Score is -4 (Poor), #74 of 89 in Pharma. Insiders sold $20K in the last 6 months (Form 4).

What does ARVN's Quality Score say?

ARVN scores -4 today, which Breakaway calls Poor. It is #74 of 89 in Pharma by Quality Score, with 1 of 14 chart checks firing. Down 6% on Nov 3, and still 9% under its Nov 2 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is ARVN's Quality Score?

ARVN scores -4 today, which Breakaway calls Poor (below zero). That is #74 of 89 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ARVN's -4.

Are insiders buying ARVN?

One insider sold $20K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is Randy Teel, President and CEO, who sold $20K on May 21.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,145 stocks ranked

See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.Then 7 days of Pro free, with a card.

What's next for Arvinas: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.